1. Home
  2. KALV vs ETW Comparison

KALV vs ETW Comparison

Compare KALV & ETW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo KalVista Pharmaceuticals Inc.

KALV

KalVista Pharmaceuticals Inc.

HOLD

Current Price

$26.83

Market Cap

1.0B

Sector

Health Care

ML Signal

HOLD

Logo Eaton Vance Corporation Eaton Vance Tax-Managed Global Buy-Write Opportunites Fund of Beneficial Interest

ETW

Eaton Vance Corporation Eaton Vance Tax-Managed Global Buy-Write Opportunites Fund of Beneficial Interest

HOLD

Current Price

$9.32

Market Cap

1.0B

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
KALV
ETW
Founded
N/A
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Investment Managers
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
1.0B
IPO Year
2014
2005

Fundamental Metrics

Financial Performance
Metric
KALV
ETW
Price
$26.83
$9.32
Analyst Decision
Strong Buy
Analyst Count
5
0
Target Price
$32.60
N/A
AVG Volume (30 Days)
5.2M
242.3K
Earning Date
07-09-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$50,000,000.00
N/A
Revenue This Year
$185.42
N/A
Revenue Next Year
$59.23
N/A
P/E Ratio
N/A
N/A
Revenue Growth
495.66
N/A
52 Week Low
$9.83
$8.22
52 Week High
$26.85
$9.60

Technical Indicators

Market Signals
Indicator
KALV
ETW
Relative Strength Index (RSI) 75.12 51.02
Support Level $14.25 $9.28
Resistance Level $26.85 $9.41
Average True Range (ATR) 0.07 0.09
MACD -0.16 -0.03
Stochastic Oscillator 77.27 51.19

Price Performance

Historical Comparison
KALV
ETW

About KALV KalVista Pharmaceuticals Inc.

KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.

About ETW Eaton Vance Corporation Eaton Vance Tax-Managed Global Buy-Write Opportunites Fund of Beneficial Interest

Eaton Vance Tax-mangd Glo Buy-write Oppo is a United States-based diversified, closed-end management investment company. The primary investment objective of the company is to provide current income and gains. The secondary objective of the fund is capital appreciation. The fund invests in a diversified portfolio of common stocks and writes call options on one or more U.S. indices on a substantial portion of the value of its common stock portfolio to generate current earnings from the option premium. Its portfolio of investments consists of capital markets, chemicals, banks, biotechnology, media, and other sectors.

Share on Social Networks: